Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$113.09 USD

113.09
11,127,844

-1.64 (-1.43%)

Updated Sep 26, 2024 04:00 PM ET

Pre-Market: $113.37 +0.28 (0.25%) 9:26 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Roche Submits Application for Tecentriq-Avastin Combo in HCC

by Zacks Equity Research

Roche (RHHBY) submits sBLA for the label expansion of the Tecentriq-Avastin combo to treat HCC patients who have not received prior systemic therapy.

Sheraz Mian headshot

Top Stock Analyst Reports for Merck, Broadcom & Sanofi

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Merck (MRK), Broadcom (AVGO) and Sanofi (SNY).

Sweta Killa headshot

What Lies Ahead for Healthcare ETFs in Q4 Earnings?

by Sweta Killa

With earnings surprise in the cards, the healthcare sector is expected to witness substantial earnings growth of 4.4% in the fourth quarter, suggesting some room for potential upside for healthcare ETFs.

Roche's Urothelial Cancer Study on Tecentriq Disappoints

by Zacks Equity Research

Roche's (RHHBY) study on Tecentriq in muscle-invasive urothelial cancer fails to meet goals.

Will Pfizer's (PFE) BioPharma Unit Boost Its Q4 Earnings?

by Zacks Equity Research

Higher sales of Pfizer's (PFE) key brands, Eliquis, Xeljanz, Ibrance in the Biopharma segment are likely to have made up for lower sales in the Upjohn group.

Kinjel Shah headshot

Pharma Stock Roundup: J&J's Mixed Q4, Roche & Novartis' New Drugs Approval in EU

by Kinjel Shah

J&J (JNJ) announces mixed Q4 results. Roche's (RHHBY) lymphoma drug, Polivy and Novartis' (NVS) Mayzent for secondary progressive multiple sclerosis (SPMS) get approval in Europe.

Signs That Your Trading Will Ruin Your Retirement - January 24, 2020

by Zacks Equity Research

From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.

BioLineRx Concludes Recruitment in Pancreatic Cancer Study

by Zacks Equity Research

BioLineRx (BLRX) closes patient recruitment in the triple combination arm of the phase IIa COMBAT/KEYNOTE-202 study on Motixafortide to treat second-line metastatic pancreatic cancer.

Pfizer (PFE) Q4 Earnings Coming Up: What's in the Cards?

by Zacks Equity Research

While Pfizer's (PFE) key drugs like Ibrance, biosimilars and strong emerging market sales are likely to have driven Q4 sales, generic competition for Lyrica is likely to have hurt the same.

Horizon Therapeutics Gets FDA Approval for Eye Drug Tepezza

by Zacks Equity Research

Horizon Therapeutics' (HZNP) Tepezza becomes the first FDA-approved therapy for treating thyroid eye disease, a rare, autoimmune disease. Stock up.

J&J's (JNJ) Q4 Earnings Surpass Estimates, Sales Fall Short

by Zacks Equity Research

J&J (JNJ) comes up with mixed fourth-quarter 2019 results.

5 Big Drug/Biotech Stocks Set to Trump Q4 Earnings Estimates

by Zacks Equity Research

Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the fourth quarter.

Is Merck & Co. (MRK) a Profitable Pick for Value Investors?

by Zacks Equity Research

Merck & Co. (MRK) stock may be a good choice for value-oriented investors right now from multiple angles.

Seattle Genetics Up More Than 40% in the Past Year: Here's Why

by Zacks Equity Research

Seattle Genetics' (SGEN) Adcetris registers strong sales in 2019. The company wins an accelerated approval for Padcev to treat urothelial cancer while other pipeline candidates also progress well.

Will J&J (JNJ) Roll Out Pharma Q4 Earnings With a Beat?

by Zacks Equity Research

J&J's (JNJ) cancer drugs are expected to have contributed significantly to fourth-quarter 2019 earnings. Generic/biosimilar headwinds are expected to have hurt Pharma unit's sales.

Kinjel Shah headshot

Pharma Stock Roundup: LLY Dermira Buyout Offer, Pipeline & Regulatory Updates

by Kinjel Shah

Lilly (LLY) offers to buy Dermira for $1.1 billion. AstraZeneca (AZN) and AbbVie (ABBV) provide pipeline updates.

Clovis Rubraca sNDA for Prostate Cancer Gets Priority Review

by Zacks Equity Research

Clovis' (CLVS) sNDA seeking label expansion of Rubraca to include BRCA-mutant advance prostate cancer gets priority review from the FDA. Stock up.

Bristol-Myers' Opdivo-Yervoy sBLA for NSCLC Accepted by FDA

by Zacks Equity Research

The FDA accepts Bristol-Myers' (BMY) sBLA for the Opdivo-Yervoy combo for the first-line treatment of patients with metastatic or recurrent NSCLC with no EGFR or ALK genomic tumor aberrations.

Will Merck (MRK) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Merck (MRK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

BioLineRx's Pancreatic Cancer Drug Gets Orphan Drug Tag in EU

by Zacks Equity Research

The European Commission bestows an orphan drug status on BioLineRx's (BLRX) lead candidate Motixafortide, currently being evaluated with Merck's Keytruda to treat pancreatic cancer. Stock up.

Merck (MRK) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the latest trading session, Merck (MRK) closed at $89.92, marking a +0.46% move from the previous day.

AstraZeneca to End Phase III Study on Fish Oil Heart Drug

by Zacks Equity Research

AstraZeneca (AZN) to discontinue STRENGTH study on its fish-oil pill Epanova in mixed dyslipidaemia on recommendation of an independent Data Monitoring Committee

Nektar Up 25% as Bristol-Myers Expands Bempeg Collaboration

by Zacks Equity Research

Nektar (NKTR) agrees to a new joint development plan with Bristol-Myers to include two new registrational studies to evaluate bempegaldesleukin plus Opdivo in bladder cancer and adjuvant melanoma.

Blueprint Medicines Posts Data From NSCLC Study on Pralsetinib

by Zacks Equity Research

Blueprint Medicines (BPMC) posts top-line data from phase I/II study on pralsetinib to treat previously treated patients with RET-fusion NSCLC. Also, it initiates the rolling NDA submission to FDA.

Verastem In-Licenses KRAS-Focused Drug From Chugai, Stock Up

by Zacks Equity Research

Verastem (VSTM) enters into an agreement with Chugai Pharmaceutical to gain worldwide rights to the latter's RAF/MEK inhibitor, CH5126766, for $3 million in upfront payment.